Skip to content
Search
Facebook
 
ADCSADCS
ADCS
Alzheimer's Disease Cooperative Study
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Study Newsletters
    • Research News
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Proposal Submission
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
  • Donate
  • Steering Committee Members
  • Staff Resources
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Study Newsletters
    • Research News
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Proposal Submission
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
  • Donate
  • Steering Committee Members
  • Staff Resources

NPR interviewed Dr. Reisa Sperling about the upcoming A4 trial and why it is unprecedented in the field of Alzheimer’s clinical research.

You are here:
  1. Home
  2. Research News
  3. NPR interviewed Dr. Reisa Sperling…

One of the longest and most anticipated Alzheimer drug studies in history is about to begin, and Dr. Reisa Sperling is wondering if people will come. It’s called the A4 study, and Sperling is the project leader.

Post navigation

PreviousPrevious post:In the largest-ever genetic analysis conducted on Alzheimer’s disease, an international group of researchers has identified 11 new genes associated with the disorder, doubling the number of known gene variants linked to it.NextNext post:The good news on Alzheimer’s: Better ways to diagnose it. Drug trials offer promise.
ADCS Research News
  • Home Based Assessments Trial Primary Paper in the Journal of Alzheimer’s & Dementia
  • “Young Latino’s Working in Alzheimer’s” Airs Tonight on UCSD TV and is Streaming on the Brain Channel
  • 40 Sites Across The Country To Test New Alzheimer’s Drug
  • Newly discovered Alzheimer’s genes lead to hope for future treatments
  • ADCS Director Howard Feldman, MD talks about the T2 Protect trial and a bright future for Alzheimer’s research
About ADCS
The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California San Diego.
Contact Us
  • E-mail:
    alzinfo@ucsd.edu
  • Phone:
    858-246-1333

Find us on:

FacebookRssMail
Location
Shipping Address:
9452 Medical Center Drive
4th Floor
La Jolla, CA 92037

Mailing Address:
9500 Gilman Dr
MC0949
La Jolla, CA 92093-0949
ADCS
Copyright 2017 Regents of the University of California.